Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 9fludarabine 8Interleukin-2 8aldesleukin 7Sunitinib 6Everolimus 6Bevacizumab 6fludarabine phosphate 5Sorafenib 5Radiotherapy 4Nivolumab 4Gene Expression Profiling 4Filgrastim 4pembrolizumab 3peginterferon alfa-2b 3Stem Cell Transplantation 3Radiotherapy, Intensity-Modulated 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3cabozantinib 2atezolizumab 2Thiotepa 2Sodium Chloride 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Mycophenolic Acid 2Mesna 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Kidney Neoplasms × VMBP protocol × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡